We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.3%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.5B
AUM Growth
+$79.1M
Cap. Flow
+$24.7M
Cap. Flow %
1.64%
Top 10 Hldgs %
31.43%
Holding
99
New
7
Increased
27
Reduced
26
Closed
7

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$14.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.9M
3
INSP icon
Inspire Medical Systems
INSP
+$11.3M
4
DHR icon
Danaher
DHR
+$11.2M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$10.4M

Top Sells

Rank Stock Value
1
ABT icon
Abbott
ABT
+$13.6M
2
TMO icon
Thermo Fisher Scientific
TMO
+$9.99M
3
ELV icon
Elevance Health
ELV
+$9.26M
4
BIIB icon
Biogen
BIIB
+$9M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$8.91M

Sector Composition

Rank Sector Weight
1 Healthcare 97.82%
2 Industrials 1.29%
3 Technology 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$376B
$60.5M 4.03%
120,000
-5,000
-4% -$2.26M
PFE icon
2
Pfizer
PFE
$143B
$58.4M 3.88%
1,000,000
– –
LLY icon
3
Eli Lilly
LLY
$1.02T
$47.1M 3.13%
170,000
+25,000
+17% +$6.34M
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$46M 3.06%
425,000
-45,000
-10% -$4.91M
ELV icon
5
Elevance Health
ELV
$81.5B
$45.8M 3.04%
98,000
-22,000
-18% -$9.26M
ABBV icon
6
AbbVie
ABBV
$443B
$45.5M 3.03%
335,000
-20,000
-6% -$2.36M
MCK icon
7
McKesson
MCK
$100B
$44.1M 2.93%
177,000
+29,000
+20% +$6.37M
JNJ icon
8
Johnson & Johnson
JNJ
$618B
$43.6M 2.9%
253,000
-17,000
-6% -$2.78M
CVS icon
9
CVS Health
CVS
$133B
$42.5M 2.83%
410,000
+10,000
+3% +$924K
BSX icon
10
Boston Scientific
BSX
$69.5B
$39.1M 2.6%
910,000
+340,000
+60% +$14.3M
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.9B
$37.2M 2.47%
290,000
+10,000
+4% +$1.31M
VRTX icon
12
Vertex Pharmaceuticals
VRTX
$121B
$36.7M 2.44%
165,000
– –
CI icon
13
Cigna
CI
$73.7B
$32.3M 2.15%
140,000
+13,000
+10% +$2.76M
MDT icon
14
Medtronic
MDT
$109B
$30.9M 2.06%
296,000
+23,000
+8% +$2.66M
ALNY icon
15
Alnylam Pharmaceuticals
ALNY
$27.5B
$29.9M 1.99%
175,000
+75,000
+75% +$13.9M
TMO icon
16
Thermo Fisher Scientific
TMO
$213B
$29.3M 1.95%
44,000
-16,000
-27% -$9.99M
COR icon
17
Cencora
COR
$60.6B
$29.2M 1.94%
218,000
+30,000
+16% +$3.69M
BIIB icon
18
Biogen
BIIB
$30B
$27.6M 1.84%
115,000
-35,000
-23% -$9M
HUM icon
19
Humana
HUM
$43.7B
$25.6M 1.71%
55,000
-2,000
-4% -$885K
BMRN icon
20
BioMarin Pharmaceuticals
BMRN
$11.6B
$23.6M 1.57%
265,000
+25,000
+10% +$2.06M
MRK icon
21
Merck
MRK
$322B
$23.1M 1.54%
300,000
– –
BDX icon
22
Becton Dickinson
BDX
$45.6B
$23M 1.53%
93,275
+33,825
+57% +$8.1M
COO icon
23
Cooper Companies
COO
$14.1B
$23M 1.53%
217,040
+37,040
+21% +$3.77M
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$22.2M 1.48%
150,000
– –
CNC icon
25
Centene
CNC
$30.7B
$21.4M 1.42%
255,000
-45,000
-15% -$3.3M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2021 Portfolio in Review

As of Q4 2021, Rhenman & Partners Asset Management held 99 positions worth $1.5B, up 5.6% from $1.42B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management's Q4 2021 filing shows 7 new, 27 increased, 26 reduced and 7 closed positions. Its largest new stake was Inspire Medical Systems: 46,373 shares worth $10.7M. The largest sale was Abbott, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Industrials and Technology.

  • Rhenman & Partners Asset Management's largest Q4 2021 buy was Inspire Medical Systems: 46,373 shares worth $10.7M.
  • Rhenman & Partners Asset Management added most to Boston Scientific in Q4 2021, an estimated $14.3M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2021 reduction was Abbott, cutting an estimated $13.6M.
  • Rhenman & Partners Asset Management fully exited Revance Therapeutics, Inc. in Q4 2021, selling an estimated $8.91M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $1.5B portfolio in Q4 2021.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 7 in Q4 2021.
  • Rhenman & Partners Asset Management's portfolio value rose 5.6% quarter-over-quarter to $1.5B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.